Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
74.66
-3.14 (-4.04%)
Mar 6, 2026, 11:30 AM EST - Market open
Bright Minds Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Bright Minds Biosciences stock have an average target of 124, with a low estimate of 80 and a high estimate of 147. The average target predicts an increase of 66.09% from the current stock price of 74.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Bright Minds Biosciences stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 4 | 4 | 3 | 3 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $115 → $145 | Strong Buy | Maintains | $115 → $145 | +94.21% | Mar 4, 2026 |
| BTIG | BTIG | Strong Buy Maintains $147 | Strong Buy | Maintains | $147 | +96.89% | Feb 17, 2026 |
| BTIG | BTIG | Strong Buy Maintains $72 → $147 | Strong Buy | Maintains | $72 → $147 | +96.89% | Jan 7, 2026 |
| BTIG | BTIG | Strong Buy Maintains $72 → $147 | Strong Buy | Maintains | $72 → $147 | +96.89% | Jan 6, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $80 | Strong Buy | Maintains | $80 | +7.15% | Jan 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.